Safety of lenalidomide (LEN) from a randomized phase III trial (MDS-004) in low-/int-1-risk myelodysplastic syndromes (MDS) with a del(5q) abnormality. Methods: We screened for the presence of the ...
The Janus kinase 2 (JAK2) protein mediates signaling from several cytokine receptors in the regulation of hematopoiesis and immune responses. Somatic mutations in human JAK2 lead to constitutive ...
New research indicates that drugs that target a cell growth pathway known as the JAK-STAT pathway are likely to be effective against certain chronic leukemias. Researchers recently discovered that a ...
ZRSR2 mutations are linked to JAK2 V617R-driven MPNs but are insufficient alone for disease progression. CRISPR-Cas9 studies showed ZRSR2 loss causes intron retention and transcriptional changes ...
Treatment with programmed cell death 1/programmed cell death ligand 1 inhibitors for Kaposi sarcoma: A systematic review and meta-analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Please provide your email address to receive an email when new articles are posted on . Patients with myelofibrosis who cleared their mutations 30 days following stem cell transplantation experienced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results